Coronavirus virulence genes with main focus on SARS-CoV envelope gene

Virus Research

Volumn 194, Issue , 2014, Pages 124-137

  DeDiego, Marta L ^a,b   Nieto Torres, Jose L ^a   Jimenez Guardeño, Jose M ^a   Regla Nava, Jose A ^a   Castaño Rodriguez, Carlos ^a   Fernandez Delgado, Raul ^a   Usera, Fernando ^a   Enjuanes, Luis ^a  

^a CSIC   (Spain)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Coronavirus; Envelope protein; Inflammation; Innate immunity; MERS CoV; SARS CoV

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CYTOKINE; ENVELOPE PROTEIN; INFLAMMASOME; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; ION CHANNEL; MEMBRANE PROTEIN; PDZ PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; BUDDING; CARBOXY TERMINAL SEQUENCE; CAUSE OF DEATH; CELL STRESS; DELETION MUTANT; DISEASE SEVERITY; EDEMA; ENVELOPE GENE; GENE DELETION; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LUNG PARENCHYMA; MESSENGER RNA SYNTHESIS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORPHOGENESIS; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PDZ DOMAIN; PROTEIN DOMAIN; PROTEIN MOTIF; SARS CORONAVIRUS; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; VIRUS GENE; VIRUS GENOME; VIRUS INFECTION; VIRUS MORPHOGENESIS; VIRUS PATHOGENESIS; VIRUS RELEASE; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE EVASION; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; VIRULENCE;

ANIMALIA; CORONAVIRUS; MURINE HEPATITIS VIRUS; MUS; SARS CORONAVIRUS; TRANSMISSIBLE GASTROENTERITIS VIRUS;

ANIMALS; GENES, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; MICE; SARS VIRUS; VIRAL ENVELOPE PROTEINS; VIRULENCE; VIRULENCE FACTORS;

EID: 84920647221     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.07.024     Document Type: Article

References (156)

1. Akerstrom S., Mirazimi A., Tan Y.J. Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. Antivir. Res. 2007, 73:219-227.
2. Almazan F., DeDiego M.L., Sola I., Zuniga S., Nieto-Torres J.L., Marquez-Jurado S., Andres G., Enjuanes L. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 2013, 4. e00650-00613.
3. Arndt A.L., Larson B.J., Hogue B.G. A conserved domain in the coronavirus membrane protein tail is important for virus assembly. J. Virol. 2010, 84:11418-11428.
4. Arpaia N., Barton G.M. Toll-like receptors: key players in antiviral immunity. Curr. Opin. Virol. 2011, 1:447-454.
5. Baas T., Roberts A., Teal T.H., Vogel L., Chen J., Tumpey T.M., Katze M.G., Subbarao K. Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus. J. Virol. 2008, 82:9465-9476.
6. Barnard D.L., Day C.W., Bailey K., Heiner M., Montgomery R., Lauridsen L., Chan P.K., Sidwell R.W. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir. Chem. Chemother. 2006, 17:275-284.
7. Boscarino J.A., Logan H.L., Lacny J.J., Gallagher T.M. Envelope protein palmitoylations are crucial for murine coronavirus assembly. J. Virol. 2008, 82:2989-2999.
8. Cameron M.J., Ran L., Xu L., Danesh A., Bermejo-Martin J.F., Cameron C.M., Muller M.P., Gold W.L., Richardson S.E., Poutanen S.M., Willey B.M., DeVries M.E., Fang Y., Seneviratne C., Bosinger S.E., Persad D., Wilkinson P., Greller L.D., Somogyi R., Humar A., Keshavjee S., Louie M., Loeb M.B., Brunton J., McGeer A.J., Kelvin D.J. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 2007, 81:8692-8706.
9. Castaño-Rodriguez C., Nieto-Torres J.L., DeDiego M.L., Jimenez-Guardeno J.M., Regla-Nava J.A., Fernandez-Delgado R., Torres J., Enjuanes L. Relevance of SARS-CoV 3a ion channel activity in virulence 2014, (unpublished results).
10. Chang Y.J., Liu C.Y., Chiang B.L., Chao Y.C., Chen C.C. Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions. J. Immunol. 2004, 173:7602-7614.
11. Chen C.C., Kruger J., Sramala I., Hsu H.J., Henklein P., Chen Y.M., Fischer W.B. ORF8a of SARS-CoV forms an ion channel: experiments and molecular dynamics simulations. Biochim. Biophys. Acta 2011, 1808:572-579.
12. Chen C.Y., Ping Y.H., Lee H.C., Chen K.H., Lee Y.M., Chan Y.J., Lien T.C., Jap T.S., Lin C.H., Kao L.S., Chen Y.M. Open reading frame 8a of the human severe acute respiratory syndrome coronavirus not only promotes viral replication but also induces apoptosis. J. Infect. Dis. 2007, 196:405-415.
13. Chen S.C., Lo S.Y., Ma H.C., Li H.C. Expression and membrane integration of SARS-CoV E protein and its interaction with M protein. Virus Genes 2009, 38:365-371.
14. Chien J.Y., Hsueh P.R., Cheng W.C., Yu C.J., Yang P.C. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology 2006, 11:715-722.
15. Chien T.H., Chiang Y.L., Chen C.P., Henklein P., Hanel K., Hwang I.S., Willbold D., Fischer W.B. Assembling an ion channel: ORF 3a from SARS-CoV. Biopolymers 2013, 99:628-635.
16. Chiu R.W., Chim S.S., Tong Y.K., Fung K.S., Chan P.K., Zhao G.P., Lo Y.M. Tracing SARS-coronavirus variant with large genomic deletion. Emerg. Infect. Dis. 2005, 11:168-170.
17. Clementz M.A., Chen Z., Banach B.S., Wang Y., Sun L., Ratia K., Baez-Santos Y.M., Wang J., Takayama J., Ghosh A.K., Li K., Mesecar A.D., Baker S.C. Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J. Virol. 2010, 84:4619-4629.
18. Cornell C.T., Kiosses W.B., Harkins S., Whitton J.L. Coxsackievirus B3 proteins directionally complement each other to downregulate surface major histocompatibility complex class I. J. Virol. 2007, 81:6785-6797.
19. 2+, calcineurin, and NF-AT. Cell 1999, 96:611-614.
20. Cruz J.L.G., Becares M., Sola I., Oliveros J.C., Enjuanes L., Zuniga S. Alphacoronavirus protein 7 modulates host innate immune response. J. Virol. 2013, 87:9754-9767.
21. Cruz J.L.G., Sola I., Becares M., Alberca B., Plana J., Enjuanes L., Zuniga S. Coronavirus gene 7 counteracts host defenses and modulates virus virulence. PLoS Pathog. 2011, 7:e1002090.
22. Curtis K.M., Yount B., Baric R.S. Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J. Virol. 2002, 76:1422-1434.
23. Dahl H., Linde A., Strannegard O. In vitro inhibition of SARS virus replication by human interferons. Scand. J. Infect. Dis. 2004, 36:829-831.
24. de Haan C.A.M., Masters P.S., Shen S., Weiss S., Rottier P.J.M. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 2002, 296:177-189.
25. de Jong A.S., Visch H.J., de Mattia F., van Dommelen M.M., Swarts H.G., Luyten T., Callewaert G., Melchers W.J., Willems P.H., van Kuppeveld F.J. The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi. J. Biol. Chem. 2006, 281:14144-14150.
26. Dedeurwaerder A., Olyslaegers D.A., Desmarets L.M., Roukaerts I.D., Theuns S., Nauwynck H.J. The ORF7-encoded accessory protein 7a of feline infectious peritonitis virus as a counteragent against interferon-alpha induced antiviral response. J. Gen. Virol. 2013, 10.1099/vir.1090.058743-058740.
27. DeDiego M.L., Alvarez E., Almazan F., Rejas M.T., Lamirande E., Roberts A., Shieh W.J., Zaki S.R., Subbarao K., Enjuanes L. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J. Virol. 2007, 81:1701-1713.
28. DeDiego M.L., Nieto-Torres J.L., Jimenez-Guardeno J.M., Regla-Nava J.A., Alvarez E., Oliveros J.C., Zhao J., Fett C., Perlman S., Enjuanes L. Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis. PLoS Pathog. 2011, 7:e1002315.
29. DeDiego M.L., Nieto-Torres J.L., Regla-Nava J.A., Jimenez-Guardeno J.M., Fernandez-Delgado R., Fett C., Castano-Rodriguez C., Perlman S., Enjuanes L. Inhibition of NF-kappaB mediated inflammation in severe acute respiratory syndome coronavirus-infected mice increases survival. J. Virol. 2014, 88:913-924.
30. DeDiego M.L., Pewe L., Alvarez E., Rejas M.T., Perlman S., Enjuanes L. Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. Virology 2008, 376:379-389.
31. Devaraj S.G., Wang N., Chen Z., Chen Z., Tseng M., Barretto N., Lin R., Peters C.J., Tseng C.T., Baker S.C., Li K. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 2007, 282:32208-32221.
32. Dosch S.F., Mahajan S.D., Collins A.R. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro. Virus Res. 2009, 142:19-27.
33. Enjuanes L., DeDiego M.L., Alvarez E., Deming D., Sheahan T., Baric R. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 2008, 133:45-62.
34. Fett C., DeDiego M.L., Regla-Nava J.A., Enjuanes L., Perlman S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J. Virol. 2013, 87:6551-6559.
35. Freundt E.C., Yu L., Park E., Lenardo M.J., Xu X.N. Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein. J. Virol. 2009, 83:6631-6640.
36. Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 2009, 83:6689-6705.
37. Frieman M., Yount B., Heise M., Kopecky-Bromberg S.A., Palese P., Baric R.S. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. 2007, 81:9812-9824.
38. Fuchizaki U., Kaneko S., Nakamoto Y., Sugiyama Y., Imagawa K., Kikuchi M., Kobayashi K. Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus. J. Med. Virol. 2003, 69:188-194.
39. Godet M., L'Haridon R., Vautherot J.F., Laude H. TGEV coronavirus ORF4 encodes a membrane protein that is incorporated into virions. Virology 1992, 188:666-675.
40. Haagmans B.L., Kuiken T., Martina B.E., Fouchier R.A., Rimmelzwaan G.F., van Amerongen G., van Riel D., de Jong T., Itamura S., Chan K.H., Tashiro M., Osterhaus A.D. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 2004, 10:290-293.
41. Haijema B.J., Volders H., Rottier P.J. Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. J. Virol. 2004, 78:3863-3871.
42. Hatada E.N., Krappmann D., Scheidereit C. NF-kappaB and the innate immune response. Curr. Opin. Immunol. 2000, 12:52-58.
43. He R., Leeson A., Andonov A., Li Y., Bastien N., Cao J., Osiowy C., Dobie F., Cutts T., Ballantine M., Li X. Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid protein. Biochem. Biophys. Res. Commun. 2003, 311:870-876.
44. Herlaar E., Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol. Med. Today 1999, 5:439-447.
45. Ho Y., Lin P.H., Liu C.Y., Lee S.P., Chao Y.C. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem. Biophys. Res. Commun. 2004, 318:833-838.
46. Hollenhorst M.I., Richter K., Fronius M. Ion transport by pulmonary epithelia. J. Biomed. Biotechnol. 2011, 2011:174306.
47. Huang C., Lokugamage K.G., Rozovics J.M., Narayanan K., Semler B.L., Makino S. SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 2011, 7:e1002433.
48. Huang C., Peters C.J., Makino S. Severe acute respiratory syndrome coronavirus accessory protein 6 is a virion-associated protein and is released from 6 protein-expressing cells. J. Virol. 2007, 81:5423-5426.
49. Huang Y., Yang Z.Y., Kong W.P., Nabel G.J. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. J. Virol. 2004, 78:12557-12565.
50. Hung A.Y., Sheng M. PDZ domains: structural modules for protein complex assembly. J. Biol. Chem. 2002, 277:5699-5702.
51. Hussain S., Perlman S., Gallagher T.M. Severe acute respiratory syndrome coronavirus protein 6 accelerates murine hepatitis virus infections by more than one mechanism. J. Virol. 2008, 82:7212-7222.
52. Ichinohe T., Pang I.K., Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat. Immunol. 2010, 11:404-410.
53. Ito M., Yanagi Y., Ichinohe T. Encephalomyocarditis virus viroporin 2B activates NLRP3 inflammasome. PLoS Pathog. 2012, 8:e1002857.
54. Jackson D., Hossain M.J., Hickman D., Perez D.R., Lamb R.A. A new influenza virus virulence determinant: the NS1 protein four C-terminal residues modulate pathogenicity. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4381-4386.
55. Jauregui A.R., Savalia D., Lowry V.K., Farrell C.M., Wathelet M.G. Identification of residues of SARS-CoV nsp1 that differentially affect inhibition of gene expression and antiviral signaling. PLos ONE 2013, 8:e62416.
56. Javier R.T., Rice A.P. Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses. J. Virol. 2011, 85:11544-11556.
57. Ji H.L., Song W., Gao Z., Su X.F., Nie H.G., Jiang Y., Peng J.B., He Y.X., Liao Y., Zhou Y.J., Tousson A., Matalon S. SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 296:L372-L383.
58. Jiang Y., Xu J., Zhou C., Wu Z., Zhong S., Liu J., Luo W., Chen T., Qin Q., Deng P. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am. J. Respir. Crit. Care Med. 2005, 171:850-857.
59. Jimenez-Guardeño J.M., Nieto-Torres J.L., DeDiego M.L., Regla-Nava J.A., Fernandez-Delgado R., Castaño-Rodriguez C., Enjuanes L. The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. PLoS Pathog. 2014, 10.1371/journal.ppat.1004320.
60. Kamitani W., Huang C., Narayanan K., Lokugamage K.G., Makino S. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat. Struct. Mol. Biol. 2009, 16:1134-1140.
61. Kanzawa N., Nishigaki K., Hayashi T., Ishii Y., Furukawa S., Niiro A., Yasui F., Kohara M., Morita K., Matsushima K., Le M.Q., Masuda T., Kannagi M. Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-kappaB activation. FEBS Lett. 2006, 580:6807-6812.
62. Kawai T., Akira S. Signaling to NF-kappaB by toll-like receptors. Trends Mol. Med. 2007, 13:460-469.
63. Kiyono T., Hiraiwa A., Fujita M., Hayashi Y., Akiyama T., Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:11612-11616.
64. Koetzner C.A., Kuo L., Goebel S.J., Dean A.B., Parker M.M., Masters P.S. Accessory protein 5a is a major antagonist of the antiviral action of interferon against murine coronavirus. J. Virol. 2010, 84:8262-8274.
65. Kopecky-Bromberg S.A., Martinez-Sobrido L., Frieman M., Baric R.A., Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 2007, 81:548-557.
66. Kumaki Y., Ennis J., Rahbar R., Turner J.D., Wandersee M.K., Smith A.J., Bailey K.W., Vest Z.G., Madsen J.R., Li J.K., Barnard D.L. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antivir. Res. 2011, 89:75-82.
67. Kumar S., Boehm J., Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2003, 2:717-726.
68. Kuo L., Masters P.S. The small envelope protein E is not essential for murine coronavirus replication. J. Virol. 2003, 77:4597-4608.
69. Lamirande E.W., DeDiego M.L., Roberts A., Jackson J.P., Alvarez E., Sheahan T., Shieh W.J., Zaki S.R., Baric R., Enjuanes L., Subbarao K. A live attenuated SARS coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 2008, 82:7721-7724.
70. Lau S.K., Lau C.C., Chan K.H., Li C.P., Chen H., Jin D.Y., Chan J.F., Woo P.C., Yuen K.Y. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J. Gen. Virol. 2013, 94:2679-2690.
71. Law A.H., Lee D.C., Cheung B.K., Yim H.C., Lau A.S. Role for nonstructural protein 1 of severe acute respiratory syndrome coronavirus in chemokine dysregulation. J. Virol. 2007, 81:416-422.
72. Le Bon A., Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 2002, 14:432-436.
73. Lei L., Ying S., Baojun L., Yi Y., Xiang H., Wenli S., Zounan S., Deyin G., Qingyu Z., Jingmei L., Guohui C. Attenuation of mouse hepatitis virus by deletion of the LLRKxGxKG region of Nsp1. PLOS ONE 2013, 8:e61166.
74. Liao Q.J., Ye L.B., Timani K.A., Zeng Y.C., She Y.L., Ye L., Wu Z.H. Activation of NF-kappaB by the full-length nucleocapsid protein of the SARS coronavirus. Acta Biochim. Biophys. Sin. 2005, 37:607-612.
75. Liao Y., Lescar J., Tam J.P., Liu D.X. Expression of SARS-coronavirus envelope protein in Escherichia coli cells alters membrane permeability. Biochem. Biophys. Res. Commun. 2004, 325:374-380.
76. Liao Y., Yuan Q., Torres J., Tam J.P., Liu D.X. Biochemical and functional characterization of the membrane association and membrane permeabilizing activity of the severe acute respiratory syndrome coronavirus envelope protein. Virology 2006, 349:264-265.
77. Liu D.X., Inglis S.C. Association of the infectious bronchitis virus-3c protein with the virion envelope. Virology 1991, 185:911-917.
78. Lopez L.A., Riffle A.J., Pike S.L., Gardner D., Hogue B.G. Importance of conserved cysteine residues in the coronavirus envelope protein. J. Virol. 2008, 82:3000-3010.
79. Lu W., Zheng B.J., Xu K., Schwarz W., Du L., Wong C.K., Chen J., Duan S., Deubel V., Sun B. Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:12540-12545.
80. Lu X., Pan J., Tao J., Guo D. SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes 2011, 42:37-45.
81. Mahlakoiv T., Ritz D., Mordstein M., DeDiego M.L., Enjuanes L., Muller M.A., Drosten C., Staeheli P. Combined action of type I and type III interferon restricts initial replication of SARS-coronavirus in the lung but fails to inhibit systemic virus spread. J. Gen. Virol. 2012, 93:2601-2605.
82. Matthay M.A., Zemans R.L. The acute respiratory distress syndrome: pathogenesis and treatment. Annu. Rev. Pathol. 2011, 6:147-163.
83. Matthews K.L., Coleman C.M., van der Meer Y., Snijder E.J., Frieman M.B. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J. Gen. Virol. 2014, 95:874-882.
84. McAuley J.L., Tate M.D., MacKenzie-Kludas C.J., Pinar A., Zeng W., Stutz A., Latz E., Brown L.E., Mansell A. Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease. PLoS Pathog. 2013, 9:e1003392.
85. McBride R., Fielding B.C. The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis. Viruses 2012, 4:2902-2923.
86. Meduri G.U., Headley S., Kohler G., Stentz F., Tolley E., Umberger R., Leeper K. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995, 107:1062-1073.
87. Melik W., Ellencrona K., Wigerius M., Hedstrom C., Elvang A., Johansson M. Two PDZ binding motifs within NS5 have roles in tick-borne encephalitis virus replication. Virus Res. 2012, 169:54-62.
88. Minakshi R., Padhan K., Rani M., Khan N., Ahmad F., Jameel S. The SARS coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS ONE 2009, 4:e8342.
89. Mogensen T.H., Paludan S.R. Molecular pathways in virus-induced cytokine production. Microbiol. Mol. Biol. Rev. 2001, 65:131-150.
90. Mortola E., Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett. 2004, 576:174-178.
91. Netland J., DeDiego M.L., Zhao J., Fett C., Alvarez E., Nieto-Torres J.L., Enjuanes L., Perlman S. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 2010, 399:120-128.
92. Netland J., Meyerholz D.K., Moore S., Cassell M., Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 2008, 82:7264-7275.
93. Neuman B.W., Adair B.D., Yeager M., Buchmeier M.J. Purification and electron cryomicroscopy of coronavirus particles. Methods Mol. Biol. 2008, 454:129-136.
94. Niemeyer D., Zillinger T., Muth D., Zielecki F., Horvath G., Suliman T., Barchet W., Weber F., Drosten C., Muller M.A. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J. Virol. 2013, 87:12489-12495.
95. Nieto-Torres J.L., Dediego M.L., Alvarez E., Jimenez-Guardeno J.M., Regla-Nava J.A., Llorente M., Kremer L., Shuo S., Enjuanes L. Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. Virology 2011, 415:69-82.
96. Nieto-Torres J.L., DeDiego M.L., Verdia-Baguena C., Jimenez-Guardeno J.M., Regla-Nava J.A., Fernandez-Delgado R., Castaño-Rodriguez C., Alcaraz A., Torres J., Aguilella V.M., Enjuanes L. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014, 10.1371/journal.ppat.1004077.
97. Nieva J.L., Madan V., Carrasco L. Viroporins: structure and biological functions. Nat. Rev. Microbiol. 2012, 10:563-574.
98. Obitsu S., Ahmed N., Nishitsuji H., Hasegawa A., Nakahama K., Morita I., Nishigaki K., Hayashi T., Masuda T., Kannagi M. Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. Arch. Virol. 2009, 154:1457-1464.
99. Oostra M., de Haan C.A., Rottier P.J. The 29-nucleotide deletion present in human but not in animal severe acute respiratory syndrome coronaviruses disrupts the functional expression of open reading frame 8. J. Virol. 2007, 81:13876-13888.
100. Ortego J., Ceriani J.E., Patino C., Plana J., Enjuanes L. Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway. Virology 2007, 368:296-308.
101. Ortego J., Escors D., Laude H., Enjuanes L. Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome. J. Virol. 2002, 76:11518-11529.
102. Pan J., Peng X., Gao Y., Li Z., Lu X., Chen Y., Ishaq M., Liu D., DeDiego M.L., Enjuanes L., Guo D. Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV replication. PLoS ONE 2008, 3:e3299.
103. Parthasarathy K., Ng L., Lin X., Liu D.X., Pervushin K., Gong X., Torres J. Structural flexibility of the pentameric SARS coronavirus envelope protein ion channel. Biophys. J. 2008, 95:39-41.
104. Pervushin K., Tan E., Parthasarathy K., Lin X., Jiang F.L., Yu D., Vararattanavech A., Soong T.W., Liu D.X., Torres J. Structure and inhibition of the SARS coronavirus envelope protein ion channel. PLoS Pathog. 2009, 5:e1000511.
105. Pewe L., Zhou H., Netland J., Tangudu C., Olivares H., Shi L., Look D., Gallagher T., Perlman S. A severe acute respiratory syndrome-associated coronavirus-specific protein enhances virulence of an attenuated murine coronavirus. J. Virol. 2005, 79:11335-11342.
106. Pugin J., Ricou B., Steinberg K.P., Suter P.M., Martin T.R. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am. J. Respir. Crit. Care Med. 1996, 153:1850-1856.
107. Rathinam V.A., Fitzgerald K.A. Cytosolic surveillance and antiviral immunity. Curr. Opin. Virol. 2011, 1:455-462.
108. Regla-Nava J.A., Nieto-Torres J.L., Jimenez-Guardeno J.M., Fernandez-Delgado R., Fett C., Castano-Rodriguez C., Perlman S., Enjuanes L., DeDiego M.L. Identification of host responses contributing to attenuation of severe acute respiratory syndrome coronaviruses containing mutated E protein. J. Virol. 2014, (in press).
109. Ruch T.R., Machamer C.E. The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus. J. Virol. 2011, 85:675-685.
110. Ruch T.R., Machamer C.E. The coronavirus E protein: assembly and beyond. Viruses 2012, 4:363-382.
111. Sainz B., Mossel E.C., Peters C.J., Garry R.F. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2004, 329:11-17.
112. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14:778-809.
113. Schaecher S.R., Stabenow J., Oberle C., Schriewer J., Buller R.M., Sagartz J.E., Pekosz A. An immunosuppressed Syrian golden hamster model for SARS-CoV infection. Virology 2008, 380:312-321.
114. Sen G.C. Viruses and interferons. Annu. Rev. Microbiol. 2001, 55:255-281.
115. Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R., Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003, 300:1148-1151.
116. Siu K.L., Kok K.H., Ng M.H., Poon V.K., Yuen K.Y., Zheng B.J., Jin D.Y. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J. Biol. Chem. 2009, 284:16202-16209.
117. Siu K.L., Yeung M.L., Kok K.H., Yuen K.S., Kew C., Lui P.Y., Chan C.P., Tse H., Woo P.C., Yuen K.Y., Jin D.Y. Middle East respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in innate antiviral response. J. Virol. 2014, 10.1128/JVI.03649-03613.
118. Smits S.L., de Lang A., van den Brand J.M., Leijten L.M., van I.W.F., Eijkemans M.J., van Amerongen G., Kuiken T., Andeweg A.C., Osterhaus A.D., Haagmans B.L. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010, 6:e1000756.
119. Smits S.L., van den Brand J.M., de Lang A., Leijten L.M., van Ijcken W.F., van Amerongen G., Osterhaus A.D., Andeweg A.C., Haagmans B.L. Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. J. Virol. 2011, 85:4234-4245.
120. Spaller M.R. Act globally, think locally: systems biology addresses the PDZ domain. ACS Chem. Biol. 2006, 1:207-210.
121. Stroher U., DiCaro A., Li Y., Strong J.E., Aoki F., Plummer F., Jones S.M., Feldmann H. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J. Infect. Dis. 2004, 189:1164-1167.
122. Sun L., Xing Y., Chen X., Zheng Y., Yang Y., Nichols D.B., Clementz M.A., Banach B.S., Li K., Baker S.C., Chen Z. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLOS ONE 2012, 7:e30802.
123. Tan Y.J., Tham P.Y., Chan D.Z., Chou C.F., Shen S., Fielding B.C., Tan T.H., Lim S.G., Hong W. The severe acute respiratory syndrome coronavirus 3a protein up-regulates expression of fibrinogen in lung epithelial cells. J. Virol. 2005, 79:10083-10087.
124. Tanaka T., Kamitani W., DeDiego M.L., Enjuanes L., Matsuura Y. Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA. J. Virol. 2012, 86:11128-11137.
125. Tang N.L., Chan P.K., Wong C.K., To K.F., Wu A.K., Sung Y.M., Hui D.S., Sung J.J., Lam C.W. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin. Chem. 2005, 51:2333-2340.
126. Teoh K.T., Siu Y.L., Chan W.L., Schluter M.A., Liu C.J., Peiris J.S., Bruzzone R., Margolis B., Nal B. The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis. Mol. Biol. Cell 2010, 21:3838-3852.
127. Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012, 76:16-32.
128. Torres J., Maheswari U., Parthasarathy K., Ng L., Liu D.X., Gong X. Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Sci. 2007, 16:2065-2071.
129. Torres J., Parthasarathy K., Lin X., Saravanan R., Liu D.X. Model of a putative pore: the pentameric alpha-helical bundle of SARS coronavirus E protein in lipid bilayers. Biophys. J. 2006, 91:938-947.
130. Triantafilou K., Kar S., Vakakis E., Kotecha S., Triantafilou M. Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax 2013, 68:66-75.
131. Underwood D.C., Osborn R.R., Bochnowicz S., Webb E.F., Rieman D.J., Lee J.C., Romanic A.M., Adams J.L., Hay D.W., Griswold D.E. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell Mol. Physiol. 2000, 279:L895-L902.
132. Varshney B., Agnihothram S., Tan Y.J., Baric R., Lal S.K. SARS coronavirus 3b accessory protein modulates transcriptional activity of RUNX1b. PLOS ONE 2012, 7:e29542.
133. Varshney B., Lal S.K. SARS-CoV accessory protein 3b induces AP-1 transcriptional activity through activation of JNK and ERK pathways. Biochemistry 2011, 50:5419-5425.
134. Verdia-Baguena C., Nieto-Torres J.L., Alcaraz A., Dediego M.L., Enjuanes L., Aguilella V.M. Analysis of SARS-CoV E protein ion channel activity by tuning the protein and lipid charge. Biochim. Biophys. Acta 2013, 1828:2026-2031.
135. Verdia-Baguena C., Nieto-Torres J.L., Alcaraz A., Dediego M.L., Torres J., Aguilella V.M., Enjuanes L. Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids. Virology 2012, 432:485-494.
136. von Brunn A., Teepe C., Simpson J.C., Pepperkok R., Friedel C.C., Zimmer R., Roberts R., Baric R., Haas J. Analysis of intraviral protein-protein interactions of the SARS coronavirus ORFeome. PLoS ONE 2007, 2:1-11.
137. Wang C.H., Liu C.Y., Wan Y.L., Chou C.L., Huang K.H., Lin H.C., Lin S.M., Lin T.Y., Chung K.F., Kuo H.P. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respir. Res. 2005, 6:42.
138. Wang G., Chen G., Zheng D., Cheng G., Tang H. PLP2 of mouse hepatitis virus A59 (MHV-A59) targets TBK1 to negatively regulate cellular type I interferon signaling pathway. PLoS ONE 2011, 6(2):e17192.
139. Wang W., Ye L., Ye L., Li B., Gao B., Zeng Y., Kong L., Fang X., Zheng H., Wu Z., She Y. Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res. 2007, 128:1-8.
140. Wathelet M.G., Orr M., Frieman M.B., Baric R.S. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J. Virol. 2007, 81:11620-11633.
141. Whitmarsh A.J., Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 1996, 74:589-607.
142. Wilson L., Gage P., Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 2006, 353:294-306.
143. Wilson L., McKinlay C., Gage P. SARS coronavirus E protein forms cation-selective ion channels. Virology 2004, 330:322-331.
144. Wong C.K., Lam C.W., Wu A.K., Ip W.K., Lee N.L., Chan I.H., Lit L.C., Hui D.S., Chan M.H., Chung S.S., Sung J.J. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004, 136:95-103.
145. Yang X., Chen X., Bian G., Tu J., Xing Y., Wang Y., Chen Z. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J. Gen. Virol. 2014, 95:614-626.
146. Ye Y., Hauns K., Langland J.O., Jacobs B.L., Hogue B.G. Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist. J. Virol. 2007, 81:2554-2563.
147. Yount B., Roberts R.S., Sims A.C., Deming D., Frieman M.B., Sparks J., Denison M.R., Davis N., Baric R.S. Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J. Virol. 2005, 79:14909-14922.
148. Zhang X., Wu K., Wang D., Yue X., Song D., Zhu Y., Wu J. Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB. Virology 2007, 365:324-335.
149. Zhao J., Falcon A., Zhou H., Netland J., Enjuanes L., Perez Brena P., Perlman S. Severe acute respiratory syndrome coronavirus protein 6 is required for optimal replication. J. Virol. 2009, 83:2368-2373.
150. Zhao J., Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 2010, 84:9318-9325.
151. Zhao L., Jha B.K., Wu A., Elliott R., Ziebuhr J., Gorbalenya A.E., Silverman R.H., Weiss S.R. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe 2012, 11:607-616.
152. Zhao L., Rose K.M., Elliott R., Van Rooijen N., Weiss S.R. Cell type-specific type I interferon antagonism influences organ tropism of murine coronavirus. J. Virol. 2011, 85:10058-10068.
153. Zheng B., He M.L., Wong K.L., Lum C.T., Poon L.L., Peng Y., Guan Y., Lin M.C., Kung H.F. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma). J. Interferon Cytokine Res. 2004, 24:388-390.
154. Zheng D., Chen G., Guo B., Cheng G., Tang H. PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res. 2008, 18:1105-1113.
155. Zust R., Cervantes-Barragan L., Habjan M., Maier R., Neuman B.W., Ziebuhr J., Szretter K.J., Baker S.C., Barchet W., Diamond M.S., Siddell S.G., Ludewig B., Thiel V. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 2011, 12:137-143.
156. Zust R., Cervantes-Barragan L., Kuri T., Blakqori G., Weber F., Ludewig B., Thiel V. Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines. PLoS Pathog. 2007, 3:e109.